'The Phase 1/2 clinical trial of VAL201 in the treatment of men with prostate cancer was closed to further recruitment on
The trial considered the safety and tolerability of drug administration, alongside pharmacokinetics and disease impact. Although the COVID-19 pandemic lockdown initially cast concern on the time schedules for data verification processes, the project remains on track to release headline results within Q3 2020, which will provide basic details of safety, tolerability and disease impact. More detailed observations on the pharmacokinetics and complete summaries of patient demographics, biochemistry and study conduct will be available when the Clinical Study Report is completed in Q4 2020.'
Following the placing announced on
Exercise of Warrant
The Company announces it has received a further notification for the exercise of a warrant over 200,000 ordinary shares in the Company at an exercise price of
Application will be made to the
For the purposes of the Disclosure and Transparency Rules, following the issue of shares detailed above as a result of the Warrant Exercise, the enlarged issued share capital of the Company will comprise 58,789,423 ordinary shares of
Warrant Update
As announced on
Business Address Update
The Company's business address has changed to Eliot Park Innovation Centre,
Contact:
Tel: +44 (0) 20 7073 2628
Email: Suzanne.Dilly@valirx.com
Web: www.valirx.com
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as 'believe', 'could', 'should' 'envisage', 'estimate', 'intend', 'may', 'plan', 'potentially', 'expect', 'will' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
(C) 2020 Electronic News Publishing, source